Following clinical trials, considerable investment and a great deal of anticipation the long-action version of diabetes drug Byetta now faces an approval decision by the Food and Drug Administration. The drug is being sold by Amylin Pharmaceuticals alongside Eli Lilly and Co.
Byetta LAR is injected just once each week, and is thought to be a key drug in the future of Amylin. The drug is also thought to be crucial for Eli Lilly. The treatment will open up a different lifestyle for people with diabetes who use the drug .
Experts anticipate an approval for the drug, following an approval by the FDA of Victoza. Both drugs are similar to GLP-1, a human hormone that boosts the production of insulin to regulate blood glucose levels. However, some experts predict a delay in the approval process.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…